Market Overview

The global neurology devices market size was USD 14.4 Billion in 2024 and is projected to reach USD 26.6 Billion by 2033, growing at a CAGR of 6.72% during 2025-2033. Key growth drivers include increasing prevalence of neurological disorders such as epilepsy, Alzheimer's disease, dementias, and cerebrovascular diseases, alongside technological advancements and a rising geriatric population. This growth is supported by expanded healthcare infrastructure and improved device innovation. 

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

Neurology Devices Market Key Takeaways

• The global neurology devices market size reached USD 14.4 Billion in 2024.
• The market is expected to grow at a CAGR of 6.72% during the forecast period 2025-2033.
• Key drivers include favorable government initiatives and expanding healthcare facilities.
• Rising incidences of neurological disorders and the growing geriatric population are primary market trends.
• North America is the largest regional market due to advanced healthcare systems.
• Regulatory hurdles pose challenges, while advancements in regenerative medicine and restorative therapies offer opportunities.

Sample Request Link: 

https://www.imarcgroup.com/neurology-devices-market/requestsample

Market Growth Factors

The neurology devices market is primarily propelled by the increasing prevalence of neurological disorders such as epilepsy, Alzheimer's disease, dementias, and cerebrovascular diseases. According to the World Health Organization, 206 million people had diabetic neuropathy in 2021. These disorders cause coordination issues, muscle weakness, and sensory loss, driving demand for precise diagnostic and monitoring devices that support effective treatment and management.

Technological advancements have led to improved neurology devices with innovative features including telemedicine capabilities for remote patient monitoring. For example, Abbott released an updated NeuroSphere myPath digital health app in April 2022 enabling clinicians to monitor patients using deep brain stimulation therapy devices. Medtronic's FDA-approved Percept RC deep brain stimulation system is another innovation allowing customized treatments for movement disorders like Parkinson's disease, essential tremor, and epilepsy.

The growing geriatric population also significantly supports market growth. Older adults are more vulnerable to neurological diseases such as dementia and stroke, increasing demand for neurological equipment and services. The World Health Organization projects that by 2050, persons aged 80 years or older will reach 426 million, intensifying the need for advanced neurology devices in healthcare settings focused on elderly care.

Market Segmentation

By Product:

• Neurostimulation Devices: Largest segment, crucial for regulating neural pathways through electrical signals or energy. Helps reduce medication dependency and supports treatment of conditions like depression and migraines.
• Neurosurgery Devices
• Interventional Neurology Devices
• Cerebrospinal Fluid Management Devices
• Others

By End User:

• Hospitals: Dominant end user, equipped for advanced neurological treatments, emergency care, and diagnostics. Hospitals can manage higher patient volumes and have specialized neurological staff.
• Ambulatory Surgery Centers
• Neurology Clinics

By Region:

• North America: Largest regional market, supported by advanced healthcare infrastructure, robust R&D activities, and government initiatives.
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa

Regional Insights

North America leads the neurology devices market, possessing the largest market share attributed to its state-of-the-art healthcare facilities and intensive research and development. Government support and a high prevalence of neurological disorders further enhance its dominance. By 2050, approximately 13 million Americans are projected to suffer from Alzheimer's disease, increasing demand for neurology solutions.

Recent Developments & News

• On January 14, 2021, Medtronic plc began the Adaptive DBS Algorithm for Personalized Therapy trial in Parkinson's disease patients, evaluating adaptive deep brain stimulation safety and efficacy.
• On January 12, 2021, ClearMind Biomedical received FDA 510(k) clearance for its Axonpen System neuroendoscope, designed to illuminate and visualize intracranial tissues and aid in surgical aspiration control.

Key Players

• Abbott
• B. Braun SE
• Boston Scientific Corporation
• Integra LifeSciences Corporation
• LivaNova PLC
• Medtronic plc
• Natus Medical Incorporated
• Nihon Kohden Corporation
• Penumbra, Inc
• Stryker Corporation

Request For Customization:

https://www.imarcgroup.com/request?type=report&id=6191&flag=E

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302